Suppression of the T-dependent Antibody Response Following Oral Exposure to Selected Polycyclic Aromatic Compounds in B6C3F1/N Mice

Victor J Johnson ^1* Cynthia Rider ² Michael I Luster ¹ Cynthia J Willson ³ Shawn Harris ⁴ Esra Mutlu ^2,5 Veronica Godfrey ² Suramya Waidyanatha ² Billie Stiffler ⁶ Brian Burback ⁶ Gary R Burleson ¹ Dori R Germolec ^2*

• ¹ Burleson Research Technologies, Inc., Morrisville, NC, United States
• ² Division of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, NC, United States
• ³ Integrated Laboratory Systems, LLC, An Inotiv Company, Morrisville, NC, United States
• ⁴ DLH, LLC., Bethesda, MD, United States
• ⁵ Office of Research and Development, United States Environmental Protection Agency, Research Triangle Park, NC, United States
• ⁶ Battelle, Columbus, OH, United States

The ability of polycyclic aromatic compounds (PACs), most notably benzo(a)pyrene [B(a)P], to suppress antibody responses in experimental animals is well documented. Very little information, however, is available on the immunotoxicity of related PACs despite their widespread presence in the environment. Additionally, there are several weaknesses in existing immunotoxicity databases for PACs in experimental animals, limiting their applicability in quantitative risk assessment. Careful characterization of strong positive and clear negative PACs is needed in order to lay the foundation for generating robust immunotoxicity data for structurally diverse PACs that have not yet been evaluated. In the current study, adult B6C3F1/N female mice were treated daily for 28 consecutive days by oral administration of B(a)P to provide dose levels ranging between 2 and 150 mg/kg bodyweight/day. In addition, phenanthrene and pyrene, non-carcinogenic PACs, were tested at dose ranges between 12.5 and 800 mg/kg bodyweight/day and 3.1 and 200 mg/kg bodyweight/day, respectively. B(a)P exposure resulted in significant decreases in lymphoid organ weights, immune cell populations in the spleen and T-dependent antibody responses (TDAR). The most sensitive indicator for immunotoxicity from B(a)P treatment was suppression of antibody responses, where an ~75% decrease occurred at a dose level of 9 mg/kg bodyweight/day and ~32% decrease at the lowest tested dose of 2 mg/kg bodyweight/day. Antibody suppression was associated with significant immune cell loss in the spleen; however, it was clear that the suppression of the TDAR was more sensitive than cell loss indicating that cell function impairments were involved. Phenanthrene treatment also resulted in suppression of the antibody response but only at dose levels ≥50 mg/kg bodyweight/day without significant effects on other parameters, while pyrene showed no significant immune effects. These studies lay the foundation for evaluating diverse PACs with a range of immunotoxicological potencies.